Selective Farnesol Isomerization to Nerolidol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing alpha-bisabolol from farnesol or nerolidol often result in mixtures containing undesirable farnesol, which is allergenic and difficult to separate due to similar boiling points with alpha-bisabolol, posing challenges for cosmetic and pharmaceutical applications.
Innovation Solution
A method involving selective isomerization of farnesol to nerolidol in the presence of alpha-bisabolol using transition metal catalysts, such as vanadium or tungsten complexes, to achieve a high molar ratio of alpha-bisabolol to farnesol, allowing for easy separation of alpha-bisabolol and conversion back to farnesol as needed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If acid-catalyzed cyclization is used to produce alpha-bisabolol from farnesol or nerolidol, then alpha-bisabolol is obtained, but farnesol remains in the mixture and is difficult to separate due to similar boiling points
Solution Approach 1:
The patent applies preliminary action by converting farnesol to nerolidol before the cyclization step. The method involves treating farnesol with a base catalyst to isomerize it to nerolidol, which then undergoes acid-catalyzed cyclization to produce alpha-bisabolol. This preliminary conversion ensures that farnesol is transformed into a reactive intermediate (nerolidol) that will cyclize efficiently, thereby eliminating the need to separate farnesol from the final product mixture.
2Ease of manufacture
If distillation is used to separate alpha-bisabolol from farnesol, then separation is attempted, but it is difficult due to almost identical boiling points
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition parameters rather than relying on physical separation parameters. Instead of attempting to separate compounds based on their similar boiling points, the method changes the chemical state of farnesol by converting it to nerolidol through base-catalyzed isomerization. This parameter change in chemical structure enables subsequent acid-catalyzed cyclization to proceed efficiently, transforming the separation problem into a chemical conversion solution.
3Manufacturing precision
If farnesol is converted to nerolidol using base catalyst, then farnesol content is reduced, but the conversion must be selective in the presence of alpha-bisabolol
Solution Approach 1:
The patent applies the intermediary principle by using a base catalyst as a mediator that selectively promotes the isomerization of farnesol to nerolidol without affecting alpha-bisabolol. The base catalyst (such as NaOH, KOH, or Cs2CO3) acts as an intermediary that facilitates the specific chemical transformation of farnesol while leaving alpha-bisabolol unchanged, thereby achieving selective conversion without requiring complex separation or protection mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively reduces farnesol content in product mixtures, enhancing the purity and safety of alpha-bisabolol for use in cosmetics and pharmaceuticals by achieving high yields of alpha-bisabolol while minimizing farnesol presence, thus addressing allergenic and separation issues.
Implementation Method 1
A method involving selective isomerization of farnesol to nerolidol in the presence of alpha-bisabolol using transition metal catalysts, such as vanadium or tungsten complexes
Data Source
AI summary
A method for converting farnesol to nerolidol in the presence of alpha-bisabolol including providing or preparing a mixture of alpha-bisabolol, farnesol, and one or more catalysts for selective isomerization of farnesol to nerolidol in the presence of alpha-bisabolol, and converting at least a portion of the farnesol to nerolidol.